Status:

COMPLETED

Effects of Gluten Digestion With ALV003

Lead Sponsor:

Alvine Pharmaceuticals Inc.

Conditions:

Celiac Disease

Eligibility:

All Genders

18-75 years

Brief Summary

This is a Phase 0, Double-blind study that will assess the effect of in vitro treatment of gluten with ALV003 or with placebo when ingested by CD Subjects.

Detailed Description

The primary objective of this study is to compare the effects of gluten treated with ALV003 vs placebo: * The clinical response by symptom measurement before and after oral challenge * The immune res...

Eligibility Criteria

Inclusion

  • Age 18-75 years
  • Well controlled Celiac Disease without flare in symptoms for the past 8 weeks
  • History of biopsy proven Celiac Disease
  • Able and willing to complete a symptom diary for 3 days prior and through 3 days post gluten challenge
  • Been on a gluten free diet for 8 weeks prior to study entry
  • Have normal celiac serology (anti- tTG level of \<20 units/mL)

Exclusion

  • Uncontrolled complications of celiac disease which in the opinion of the Investigator would impact their immune response, or pose an increased risk to the subject. (example: like type 1 diabetes or other autoimmune disease)
  • Pregnant or breast feeding women, subjects of childbearing potential to use two methods of contraception
  • Concomitant medications such as over the counter digestive enzymes, immunosuppressive therapies, anticoagulants, NSAIDs. Chronic medications for well-controlled chronic conditions are allowed.
  • Clinically significant abnormal lab values, as determined by the PI:
  • Untreated or active peptic ulcer disease, esophagitis, motility disorders or any gastrointestinal diseases.
  • Positive pregnancy test within 7 days prior to study drug administration
  • Known allergy or hypersensitivity to E.coli or E.coli derived proteins

Key Trial Info

Start Date :

May 1 2008

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

June 1 2008

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT00859391

Start Date

May 1 2008

End Date

June 1 2008

Last Update

June 11 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Nucleus Networks Limited

Melbourne, Victoria, Australia, 3004